Structure Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
GPCR$21.41+5.2%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| | | | | | | | |
| · · SEPTEMBER 30, · · DECEMBER 31, · | |||||||
| · 2024 · 2023 | |||||||
| Assets | | | | | | | |
| Current assets: · · | |||||||
| Cash and cash equivalents | | $172,130 | | $129,792 | | ||
| Short-term investments | | 743,156 | | 337,531 | | ||
| Prepaid expenses and other current assets | | 8,365 | | 6,285 | | ||
| Total current assets | | 923,651 | | 473,608 | | ||
| Property and equipment, net | | 3,735 | | 3,228 | | ||
| Operating right-of-use assets | | 4,009 | | 5,136 | | ||
| Other non-current assets | | 1,822 | | 45 | | ||
| Total assets | | $933,217 | | $482,017 | | ||
| Liabilities and shareholders’ equity | | | | ||||
| Current liabilities: | | | | ||||
| Accounts payable | | $8,447 | | $4,742 | | ||
| Accrued expenses and other current liabilities | | 23,275 | | 18,558 | | ||
| Operating lease liabilities, current portion | | 1,712 | | 1,440 | | ||
| Total current liabilities | | 33,434 | | 24,740 | | ||
| Operating lease liabilities, net of current portion | | | 2,673 | | | 4,013 | |
| Other non-current liabilities | | | 309 | | | 298 | |
| Total liabilities | | 36,416 | | 29,051 | | ||
| Commitments and contingencies (Note 5) | | | | ||||
| Shareholders’ equity: | | | | | |||
| Undesignated shares – $0.0001 par value; 100,000 shares authorized as of September 30, 2024 and December 31, 2023 | | | — | | | — | |
| Ordinary shares – $0.0001 par value; 500,000 shares authorized as of September 30, 2024 and December 31, 2023; 171,762 and 139,220 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | | 17 | | 14 | | ||
| Additional paid-in capital | | 1,186,564 | | 659,003 | | ||
| Accumulated other comprehensive income | | 2,839 | | 521 | | ||
| Accumulated deficit | | (292,619) | | (206,572) | | ||
| Total shareholders’ equity | | 896,801 | | 452,966 | | ||
| Total liabilities and shareholders’ equity | | $933,217 | | $482,017 | | ||
| | | | | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.